Misonix Reports First Quarter Fiscal Year 2018 Financial Results

FARMINGDALE, N.Y., Nov. 7, 2017 /PRNewswire/ -- Misonix (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today financial results for the first quarter of fiscal year 2018, ended September 30, 2017.

Financial Highlights for the First Quarter:

• Revenue for the first quarter of fiscal year 2018 was $7.3 million, an increase of 18% compared with $6.2 million in the previous year’s first quarter.
• Consumables sales in the United States increased 25% to $4.1 million in the first quarter of the new fiscal year compared to $3.3 million in the comparable quarter of fiscal 2017.
• The gross profit percentage for the quarter was 70.1% primarily from a strong mix of higher margin consumables, compared to 69.0% in last year’s first quarter.
• For the first quarter of fiscal year 2018, the Company reported a net loss of $(1.2) million, or $(0.14) per diluted share, compared to a net loss of $(0.5) million, or $(0.07) per diluted share, in the first quarter of fiscal year 2017.
• At September 30, 2017, the Company maintained cash of $10.5 million with no long-term debt.

Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, said, “Sales orders continued to be strong in the first quarter of fiscal year 2018, with double-digit revenue growth, picking up where we left off in fiscal 2017. Total revenue increased 18% in the first quarter of the new year primarily attributable to a 25% increase in domestic consumables sales. A significant contribution to the increase in domestic sales was made by the addition of new clinical sales specialists to support the sales activities of our distribution channel. The channel, coupled with our team of 28 clinical sales specialists, was successful in driving a 35% increase in BoneScalpel revenue in the U.S. over the prior year. We are making steady progress with the surgical community, and the hospitals where they practice, to further embed our technology in their respective surgical suites.”

“At the recent 32^nd Annual Meeting of the North American Spine Society,” Mr. Vizirgianakis continued, “Dr. Wade Jensen of the Center for Neurosciences, Orthopaedics & Spine (“CNOS”) presented data showing a significant reduction in the use of bone grafting material when the Misonix BoneScalpel is employed compared to the use of standard power drill instruments. An estimated $1.9 billion is spent annually on bone graft substitutes. This is valuable data as we are able to show that our products contribute significant value to the overall healthcare system by reducing costs in spinal fusion procedures.”

The Company also recently entered into its most significant license, royalty and manufacturing agreement with Hunan Xing Hang Rui Kang Bio-Technologies Co., Ltd., a Chinese corporation, where Misonix will receive at least $11 million in revenue and royalties over the next four years, and further strengthen its balance sheet.

Conference Call
The Company has scheduled a conference call for Tuesday, November 7, 2017, at 4:30 pm ET to review the results.

Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-6579 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company’s website at www.misonix.com.

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10113569. A webcast replay will be available in the Investor Relations section of the Company’s website at www.misonix.com for 30 days.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Financial Tables to Follow

 MISONIX INC. and Subsidiaries Consolidated Statements of Operations (Unaudited) For the three months ended September 30, ------------- 2017 2016 ---- ---- Net sales $7,280,723 $6,171,625 Cost of goods sold 2,177,355 1,912,007 --------- --------- Gross profit 5,103,368 4,259,618 Operating expenses: Selling expenses 3,570,713 3,325,687 General and administrative expenses 2,573,131 1,931,821 Research and development expenses 901,274 492,084 Total operating expenses 7,045,118 5,749,592 --------- --------- Loss from operations (1,941,750) (1,489,974) Other income (expense): Interest income 13 19 Royalty income and license fees 452,971 944,068 Other (4,458) (1,996) ------ ------ Total other income 448,526 942,091 ------- ------- Loss from operations before income taxes (1,493,224) (547,883) Income tax benefit (281,000) (26,000) Net loss $(1,212,224) $(521,883) =========== ========= Net loss per share - Basic $(0.14) $(0.07) ====== ====== Net loss per share - Diluted $(0.14) $(0.07) ====== ====== Weighted average shares - Basic 8,958,405 7,809,385 Weighted average shares - Diluted 8,958,405 7,809,385 

 MISONIX INC. and Subsidiaries Consolidated Balance Sheets September 30, June 30, 2017 2017 ---- ---- (unaudited) Assets Current assets: Cash and cash equivalents $10,528,041 $11,557,071 Accounts receivable, respectively less allowance for doubtful accounts of $96,868 and $96,868, 4,153,511 5,133,389 Inventories, net 5,206,025 4,992,434 Prepaid expenses and other current assets 504,653 918,899 ------- ------- Total current assets 20,392,230 22,601,793 Property, plant and $7,794,580, equipment, respectively net of accumulated amortization and depreciation of $8,134,134 and 3,842,419 3,730,203 Patents, net of accumulated amortization of $1,025,930 and $995,568, respectively 715,177 719,136 Goodwill 1,701,094 1,701,094 Intangible and other assets 280,684 282,876 Deferred income tax 5,524,422 4,334,547 Total assets $32,456,026 $33,369,649 =========== =========== Liabilities and shareholders’ equity Current liabilities: Accounts payable $2,106,506 $1,861,228 Accrued expenses and other current liabilities 1,815,527 3,346,138 --------- --------- Total current liabilities 3,922,033 5,207,366 Deferred lease liability 7,016 9,354 Deferred income 8,989 13,087 ----- ------ Total liabilities 3,938,038 5,229,807 Commitments and contingencies Shareholders’ equity: Common stock, issued $.01 par and value- outstanding shares in each authorized period, 20,000,000; respectively 9,365,666 and 9,357,166 shares 93,657 93,572 Additional paid-in capital 37,490,220 36,808,810 Accumulated deficit (9,065,889) (8,762,540) ---------- ---------- Total shareholders’ equity 28,517,988 28,139,842 ---------- ---------- Total liabilities and shareholders’ equity $32,456,026 $33,369,649 =========== =========== 

 Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 jdwyer@misonix.com mson@lythampartners.com 

View original content with multimedia:http://www.prnewswire.com/news-releases/misonix-reports-first-quarter-fiscal-year-2018-financial-results-300551475.html

SOURCE Misonix, Inc.